Macrophage activation syndrome (MAS) is a severe, potentially life-threatening complication of childhood systemic inflammatory disorders, primarily systemic juvenile idiopathic arthritis (JIA). It is characterized by pancytopenia, liver insufficiency, coagulopathy, and neurologic symptoms and is thought to be caused by the activation and uncontrolled proliferation of T lymphocytes and macrophages, leading to cytokine overproduction [1, 2] .
Clinical features
The clinical presentation of MAS is generally acute and can be dramatic. Typically, patients become acutely ill with the sudden onset of nonremitting high fever, hepatosplenomegaly, lymphoadenopathy, profound depression of all three blood cell lines (leukopenia, anemia, and thrombocytopenia), and elevated serum liver enzymes. High concentrations of triglycerides and lactate dehydrogenase and low sodium levels are observed consistently. There is usually an abnormal coagulation profile, with prolonged prothrombin activity and partial thromboplastin time, hypofibrinogenemia, and the presence of fibrin degradation products. As a result, a patient may have purpura, easy bruising, and mucosal bleeding. Central nervous system dysfunction occurs frequently and may cause lethargy, irritability, disorientation, headache, seizures, or coma. Occasionally, renal, pulmonary, and cardiac involvement has been reported. In children with systemic JIA, the clinical picture may mimic sepsis or a flare-up of the underlying disease. However, the pattern of nonremitting fever is different from the remitting high-spiking fever seen in systemic JIA. Moreover, patients may show a paradoxical improvement in the underlying inflammatory disease at the onset of MAS, with the disappearance of the signs and symptoms of arthritis and a decrease in the erythrocyte sedimentation rate. The pathognomonic feature of the syndrome is seen on bone marrow examination, which reveals numerous well-differentiated macrophages actively phagocytosing hematopoietic cells. Such cells may be found in various organs and may account for many of the systemic manifestations.
Hyperferritinemia is an important laboratory hallmark of MAS that has received little attention to date. Phagocytic macrophages are thought to be an important source of serum ferritin [3] . In vitro studies have shown that intracellular ferritin accumulates markedly during the maturation of monocytes into macrophages and that cultured monocytes in iron-containing medium or in the phago- cytic process of erythrocytes produce ferritin rapidly [4, 5] . Very high ferritin levels are commonly encountered in disorders characterized by histiocytic proliferation and active phagocytosis of erythrocytes, such as malignant histiocytosis and virus-associated hemophagocytic syndrome [6] . A sharp increase in ferritin, often more than 10,000 ng/mL, has been reported in the acute phase of MAS [7] [8] [9] . Furthermore, a good correlation between the ferritin level and response to therapy was found, with a rapid decrease in ferritin associated with a favorable course of MAS [7] . These observations indicate that measurement of the serum ferritin level may assist in the diagnosis of MAS and may be a useful indicator of disease activity, therapy response, and prognosis. Table  1 summarizes the main features of MAS occurring in the context of childhood systemic inflammatory disorders.
Epidemiology
The exact incidence of MAS in childhood systemic inflammatory disorders is unknown. Although it is considered a rare complication, it is probably more common than previously thought. To date, approximately 100 cases have been reported in the literature [1,10•, 11•,12•] . MAS affects most commonly children with systemic JIA but has been observed in different subtypes of JIA or in other systemic diseases such as systemic lupus erythematosus (SLE). It generally develops in the earlier phases of the underlying disease and may occasionally be the presenting manifestation, but occurrence as late as 14 years after diagnosis has been reported. In most patients, the primary disease is clinically active at the onset of MAS, but the syndrome may also develop during quiescent phases.
Although MAS may occur without any identifiable precipitating factor, it has been related to a number of triggers, including a flare-up of the underlying disease, aspirin or other nonsteroidal anti-inflammatory drug toxicity, viral infections, a second injection of gold salts, and sulfasalazine therapy. A young girl with systemic JIA was described who developed MAS shortly after the first methotrexate (MTX) dose in the apparent absence of any triggering event, suggesting that MAS could have been a direct consequence of MTX toxicity [7] . The short time interval (24 hours) between MTX dosing and the onset of MAS and the characteristics of clinical symptoms, particularly the occurrence of intense and generalized pruritus, argued for a hypersensitivity or idiosyncratic reaction, a mechanism similar to that hypothesized in the pathogenesis of MAS associated with gold salt injections. This report reinforces a previous observation of a possible relationship between MTX toxicity and MAS [13] and suggests that MTX may act as an inciting factor of MAS in children with systemic JIA.
Pathogenesis
The exact cause of MAS is poorly understood. [20, 21] . It has been suggested that perforin may also control lymphocyte proliferation [19, 22] . Perforin deficiency may therefore lead to persistent lymphocyte activation associated with production of large amounts of interferon-␥ and granulocyte-macrophage colony-stimulating factor, which are important macro- 
Nomenclature and classification
The clinical syndrome of acute hemorrhagic, hepatic, and neurologic abnormalities in association with systemic JIA was first described by Hadchouel et al. [25] 
Diagnostic guidelines
Macrophage activation syndrome is a serious complication of childhood systemic inflammatory disorders that is associated with considerable morbidity and death. Early recognition of its clinical features and immediate therapeutic intervention to produce a rapid clinical response are therefore critical. However, the diagnosis of MAS, particularly in its early phase, can be difficult. In patients with systemic JIA, a condition characterized by repetitive flares, the onset of MAS may be confused with a disease exacerbation; other important differential diagnoses include intercurrent infections and side effects of medications. The recognition of MAS can be problematic in patients with SLE because it may mimic the clinical features of the underlying disease. In a young patient reported recently, this complication presented as unexplained fever and cytopenia, thus suggesting a SLE flare. The diagnosis was facilitated by the absence of other clinical or serologic indicators of SLE exacerbation or signs of infection [29] .
The difficulties in making the diagnosis and the recent therapeutic advances (see below) emphasize the need for diagnostic tools and well-established diagnostic guidelines. Diagnostic criteria would be also important for research purposes and use in publications. To identify potential criteria for MAS complicating systemic JIA, the diagnostic sensitivity and specificity of the main components of the clinical and laboratory picture of MAS were recently evaluated [12•] . The features of 109 cases of MAS seen in 88 patients reported in the literature or observed by the authors were compared with those of a cohort of control patients with a confusable condition, which included 35 patients with systemic JIA assessed at the time of their first disease flare. The variables that showed the highest (Ն0.75) sensitivity and specificity for MAS were ferritin (Ն10,000 ng/mL), triglycerides (Ն160 mg/dL), aspartate aminotransferase (Ն40 IU/mL), fibrinogen (Յ250 mg/dL), alanine aminotransferase (Ն40 IU/mL), ␥-glutamyl transferase (Ն40 IU/mL), platelet count (Յ150,000/mm 3 ), and bone marrow aspirate showing hemophagocytosis, hepatomegaly, and splenomegaly. Variables that did not prove sufficiently sensitive and specific included fever (Ն38°C), lymphoadenopathy, neurologic manifestations, arthritis, rash, hemorrhages, leukocyte count (Յ4,000/mm 3 ), erythrocyte sedimentation rate (Յ50 mm/h), lactate dehydrogenase (Ն900 IU/mL), bilirubin (Ն1.2 mg/dL), and serum sodium (Յ130 mEq/L).
Management
The treatment strategy for MAS is usually based on the parenteral administration of high doses of corticosteroids. However, there have been some fatalities in reported series, even among patients treated with massive doses of corticosteroids [1,10•,11•] . The administration of high-dose intravenous immunoglobulins, cyclophosphamide, plasma exchange, and etoposide has provided conflicting results. The use of cyclosporin A was recently advocated based on its proven benefit in the management of other disorders affecting macrophages such as primary HLH [16] . Cyclosporin A proved effective in treating severe or corticosteroid-resistant MAS [7, 29, 30] . In some patients, the introduction of this drug exerted a "switch-off" effect on the disease process, leading to resolution of fever and improvement of laboratory abnormalities within 12 to 24 hours [29] . Although the exact mechanism by which cyclosporin A achieves immunosuppression is unknown, it is believed to exert its major effects by the suppression of the early steps in T-cell activation, leading to failure to activate the transcription of early genes such as those encoding for cytokines [31] . Cyclosporin A has also been shown to affect macrophage production of IL-6, IL-1, and TNF-␣ and to inhibit the expression of inducible nitric oxide synthetase and cyclooxygenase-2 in macrophages, leading to decreased production of nitric oxide and prostaglandin E 2 [32] [33] [34] . Furthermore, it has proven able to inhibit the expression of key cell surface costimulatory molecules, thus altering the antigen-presenting function of dendritic cells for Tcell activation [35] . The demonstration of the distinctive efficacy of cyclosporin A has led some authors to propose using this drug as first-line treatment in MAS occurring in childhood systemic inflammatory disorders [29, 30] .
Based on the observation of increased serum levels of TNF-␣ in patients with MAS [16, 17] and the notion that this cytokine may play a central role in its pathogenesis, it has been hypothesized that rapid blocking of TNF-␣ activity may provide another efficient way to reduce the consequences of excessive activation of macrophages. Prahalad et al. [8] evaluated the use of the anti-TNF-␣ agent etanercept in a boy with probable systemic JIA who developed MAS that required large doses of corticosteroids to control symptoms. The addition of etanercept (0.4 mg twice weekly) 4 weeks after the onset of MAS was followed by dramatic improvement of symptoms within 24 hours after the first dose, which was paralleled by normalization of the erythrocyte sedimentation rate after four doses of etanercept. Over the next 5 weeks, prednisone was tapered completely without recurrence of symptoms. The outcome in this patient suggests that etanercept might be an effective adjunctive therapeutic agent in MAS.
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